SHORT MINI-FUTURE - BIOGEN IDEC | Market Closed - Deutsche Boerse AG 19:01:47 21/06/2024 BST | ||
| 12.7 EUR | +2.01% |
|
| Current month | +0.24% | ||
| 1 month | +6.05% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 21/06/24 | 12.7 | +2.01% |
| 20/06/24 | 12.45 | -1.35% |
| 19/06/24 | 12.62 | +1.12% |
| 18/06/24 | 12.48 | +1.46% |
| 17/06/24 | 12.3 | +2.33% |
Delayed Quote Deutsche Boerse AG
Last update June 21, 2024 at 07:01 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VV7EJ9 |
| ISIN | DE000VV7EJ96 |
| Date issued | 29/09/2022 |
| Strike | 358.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 8.75 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.77 € |
|---|---|
| Lowest since issue | 3.2 € |
| Spread | 0.03 € |
| Spread % | 0.24% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
225.6
USD
Average target price
284.6
USD
Spread / Average Target
+26.18%
- Stock Market
- Certificates
- Certificat
